Home › Research › Biomarkers
Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration
Makrina Daniilidou, Ulf Öhlund-Wistbacka, Göran Hagman, Anna Rosenberg, Nicholas Ashton, Henrik Zetterberg, Kaj Blennow, Anna Matton et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-12
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Plasma biomarkers were associated with comorbidities and metabolites such as estimated glomerular filtration rate, homocysteine, and high-density lipoprotein. Phosphorylated tau (p-tau)/amyloid beta (Aβ)42 and p-tau217 had excellent performances in AD pathology classification (AUCs > 0.938). Adjusting for comorbidity measures significantly improved the diagnostic accuracy of Aβ42/40. In conclusion, plasma biomarkers performed robustly despite comorbidity associations, with p-tau217 emerging as the strongest discriminator. These findings support their potential as diagnostic tools in clinical settings. HIGHLIGHTS: Plasma biomarkers for Alzheimer's disease (AD) were assessed in a real-world memory clinic population. Kidney dysfunction and cardiovascular risk factors influenced plasma biomarker levels. Phosphorylated tau (p-tau)217 and p-tau217/amyloid beta (Aβ)42 ratio showed strongest association with AD pathology. Aβ42/40 ratio's accuracy was improved by including comorbidities into the diagnostic algorithms.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Daniilidou, M., Öhlund-Wistbacka, U., Hagman, G., Rosenberg, A., Ashton, N., Zetterberg, H., et al. (2025). Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70931
Vancouver
Daniilidou M, Öhlund-Wistbacka U, Hagman G, Rosenberg A, Ashton N, Zetterberg H, et al. Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70931. PMID: 41326959.
BibTeX
@article{daniilidou2025-41326959,
author = {Daniilidou, Makrina and Öhlund-Wistbacka, Ulf and Hagman, Göran and Rosenberg, Anna and Ashton, Nicholas and Zetterberg, Henrik and Blennow, Kaj and Matton, Anna and others},
title = {{Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70931},
pmid = {41326959},
url = {https://doi.org/10.1002/alz.70931}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma biomarkers were associated with comorbidities and metabolites such as estimated glomerular filtration rate, homocysteine, and high-density lipoprotein.
- Phosphorylated tau (p-tau)/amyloid beta (Aβ)42 and p-tau217 had excellent performances in AD pathology classification (AUCs > 0.938).
- Adjusting for comorbidity measures significantly improved the diagnostic accuracy of Aβ42/40.
- In conclusion, plasma biomarkers performed robustly despite comorbidity associations, with p-tau217 emerging as the strongest discriminator.
- These findings support their potential as diagnostic tools in clinical settings.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 26 of the 56 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41326959) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 26 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 26 of the 56 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
693 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.